STOCK TITAN

Solésence Supports Landmark Report on UV Safety in the United Kingdom as Member of UV Safety Coalition

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Solésence (Nasdaq:SLSN) announced support for a landmark UK report, “A Preventable Crisis: The Case for a National UV Safety Strategy.” The report, led by the UK APPG for Beauty, Hair & Wellbeing and backed by the UV Safety Coalition, calls for a national UV safety strategy.

Recommendations focus on year-round UV protection, public education, better access to protection products, and treating UV protection as an essential good. Solésence participates in the UV Safety Coalition and plans to help implement non-governmental recommendations and promote daily UV protection behaviors in the UK.

Loading...
Loading translation...
Argus May 15 session
-7.63% close to close Open Argus
Details

News Market Reaction – SLSN

On May 15, the first trading day after this news, SLSN closed 7.63% below the previous close.

Data tracked by StockTitan Argus for the May 15 session.

Key Figures

Melanoma projection: 9% increase Projection year: 2038 WHO classification: Group 1 +4 more
Melanoma projection
9% increase
Melanoma cases in the U.K. projected by 2038
Projection year
2038
Year by which melanoma cases are projected to rise in the U.K.
WHO classification
Group 1
WHO classification of ultraviolet (UV) radiation as a carcinogen
Report recommendations
29 recommendations
Number of recommendations in the UV safety report
Campaign history
40-year success
Duration of Australia’s 'Slip, Slop, Slap!' initiative cited as model
Inquiry duration
Year-long inquiry
Length of the APPG’s inquiry into UV safety in the U.K.
Launch date
May 13
Date the UV safety report was launched at British Parliament

Historical Context

5 past events · Latest: May 12
5 events
  1. May 12

    Q1 2026 earnings

    24h Move
    -17.3%

    Revenue decline and shift from prior net income to net loss.

  2. May 11

    Technology launch

    24h Move
    +11.1%

    Launch of WHSPR™ and Chromalüm™ skin health platforms for partners.

  3. Apr 28

    Earnings date set

    24h Move
    -5.1%

    Announcement of Q1 2026 earnings release and conference call timing.

  4. Apr 27

    Board appointment

    24h Move
    +14.9%

    Addition of independent director Marc James to key board committees.

  5. Mar 31

    FY 2025 earnings

    24h Move
    +5.4%

    Record 2025 revenue growth with higher Q4 gross margin and new patents.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

ultraviolet (UV) radiation, group 1 carcinogen, melanoma
3 terms
ultraviolet (UV) radiation medical
"lacks a cohesive national strategy to mitigate the impact of ultraviolet (UV) radiation"
Invisible energy from the sun and certain lamps that sits just beyond visible light and can damage living tissue and materials, like an invisible sunlight that can sunburn skin or fade fabrics. Investors should care because ultraviolet exposure shapes demand and risk across industries—health and safety rules, product durability, medical sterilization devices, and liability or regulatory costs—so changes in exposure, technology or rules can affect revenues and expenses.
group 1 carcinogen medical
"ultraviolet (UV) radiation, which the World Health Organization (WHO) classifies as a Group 1 carcinogen"
A group 1 carcinogen is an agent or substance that authoritative health bodies have concluded causes cancer in humans, based on strong scientific evidence. For investors this matters because such a designation can prompt regulatory restrictions, product recalls, lawsuits or shifts in consumer behavior—similar to a widely recognized danger label that often forces companies to change products, disclose liabilities, or face higher costs and lost sales.
melanoma medical
"With melanoma cases projected to rise by 9% by 2038 according to Cancer Research U.K."
Melanoma is a serious form of skin cancer that starts in the cells that give skin its color and can grow quickly, often spreading to other parts of the body if not caught early. Investors watch melanoma because its incidence, new treatments, clinical trial results, and regulatory approvals can meaningfully affect drug and device makers’ sales, healthcare costs, and insurer liabilities—similar to how a major product success or failure moves value in other industries.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

The report, led by the United Kingdom’s APPG for Beauty, Hair & Wellbeing, calls for a national strategy to combat UV exposure, including Government support to enable access to adequate protection, build public awareness and combat misinformation.

Solésence with British Beauty Council

From left the photo includes: Carolyn Harris, MP, Chair of the APPG for Beauty, Hair & Wellbeing, Victoria Brownlie MBE, Chief Policy & Sustainability Officer, British Beauty Council, Emma Harper, Executive Director, Strategy, Marketing, and Communications, Solésence, Jacqui Burchell, Chief Commercial Officer (CCO), British Beauty Council.

ROMEOVILLE, Ill., May 14, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN) a leader in scientifically-driven health care solutions across beauty and life science categories, today announced its support of the recommendations presented in a landmark report, "A Preventable Crisis: The Case for a National UV Safety Strategy," led by the U.K.’s All-Party Parliamentary Group (APPG) for Beauty, Hair & Wellbeing.

Launched on May 13 during a dedicated event at British Parliament, the report is a result of a comprehensive year-long inquiry into UV safety in the U.K. by the APPG, supported by the UV Safety Coalition, of which Solésence is a member.

Key findings from the report warn that the U.K. currently lacks a cohesive national strategy to mitigate the impact of ultraviolet (UV) radiation, which the World Health Organization (WHO) classifies as a Group 1 carcinogen. With melanoma cases projected to rise by 9% by 2038 according to Cancer Research U.K., the APPG is calling for a radical shift in how the Government and public perceive UV protection.

"We must stop short-term thinking about sun protection. For too long, we have relied on seasonal, holiday messaging that reinforces the dangerous myth that UV safety is only for the summer,” said Carolyn Harris MP, Chair of the APPG for Beauty, Hair & Wellbeing. “We are calling on the Government to lead a sustained, national campaign—built on cross-party consensus—that mirrors the 40-year success of Australia’s 'Slip, Slop, Slap!' initiative."

The report’s 29 recommendations share a common theme of making UV protection a routine part of daily life through campaigns that aim to shift how people think about skin health and UV protection, requiring increased access and education. Following the launch of the report, the UV Safety Coalition will work to implement the report’s non-governmental recommendations and engage with industry leaders to build a plan for executing these initiatives.

“The multi-pronged recommendations in this report, from awareness and education campaigns to the categorization of UV protection as an essential good, have the opportunity to benefit human health and longevity,” said Emma Harper, Executive Director of Strategy, Marketing, and Communications at Solésence, who attended the launch event. “Our goal at Solésence is to enhance people’s lives by creating skin health solutions that fit every consumer’s skin type, tone, needs, and lifestyle. We are honored to be part of the UV Safety Coalition and to help raise awareness of the dangers of UV exposure and support the adoption of comprehensive UV protection campaigns that target education and accessibility to products in order to drive daily UV protection behaviors.”

More information and the full report can be found on the APPG for Beauty, Hair & Wellbeing’s website here: https://www.baw-appg.co.uk/

About Solésence, Inc.

Solésence, Inc. (Nasdaq: SLSN), is a leader in scientifically-driven health care solutions across beauty and life science categories. With a mission to deliver joy through innovation, inclusivity and the science of beautiful skin, we have redefined mineral-based sun protection by maximizing transparency, effectiveness, aesthetics, and wearability — empowering individuals to embrace beauty on their own terms. Combining best-in-class skin health solutions with the celebration of self-care, we allow brands to deliver unique product claims and attributes by seamlessly integrating protection, prevention, and treatment technologies into daily use products. Learn more at solesence.com.

About the APPG for Beauty, Hair & Wellbeing

The APPG provides a forum for parliamentary discussion to support the beauty and wellbeing industry and investigate key issues facing the sector. The Secretariat for the Group is the British Beauty Council.

Forward-Looking Statements

This press release contains words such as “expects,” “shall,” “will,” “believes,” and similar expressions that are intended to identify forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements in this announcement are made based on the Company’s current beliefs, known events and circumstances at the time of publication, and as such, are subject in the future to unforeseen risks and uncertainties that could cause the Company’s results of operations, performance, and achievements to differ materially from current expectations expressed in, or implied by, these forward-looking statements. These risks and uncertainties include, without limitation, the following: a decision by a customer to cancel a purchase order or supply agreement in light of the Company’s dependence on a limited number of key customers; uncertain demand for, and acceptance of, the Company’s engineered materials, ingredients, and fully formulated products; the Company’s manufacturing capacity and product mix flexibility in light of customer demand; the Company’s limited marketing experience; changes in development and distribution relationships; the impact of competitive products and technologies; the Company’s dependence on patents and protection of proprietary information; the resolution of litigation in which the Company may become involved; the impact of any potential new government regulations that could be difficult to respond to or too costly to comply with while remaining financially viable; the ability of the Company to maintain an appropriate electronic trading venue; and other factors described in the Company’s Form 10-K filed March 31, 2026. In addition, the Company’s forward-looking statements could be affected by general industry and market conditions and growth rates. Except as required by federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties, or other contingencies.

Media Contact:
media@solesence.com

Investor Relations Contact:
investors@solesence.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0ce1f2dd-8447-4b3f-8f4f-18dcb6769641


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Solésence (Nasdaq:SLSN) announce on May 14, 2026 about UV safety in the UK?

Solésence announced its support for a UK parliamentary report calling for a national UV safety strategy. According to Solésence, the report seeks better access to UV protection, stronger public education, and long-term campaigns to make daily UV protection routine.

What is the UK UV safety report supported by Solésence (SLSN) and the UV Safety Coalition?

The report, titled “A Preventable Crisis: The Case for a National UV Safety Strategy,” outlines 29 recommendations on UV safety. According to Solésence, it urges a cohesive UK strategy covering awareness campaigns, improved access to protection, and rethinking UV protection as a daily health priority.

How is Solésence (SLSN) involved in the UV Safety Coalition’s work in the United Kingdom?

Solésence is a member of the UV Safety Coalition supporting the UK APPG’s UV safety efforts. According to Solésence, the coalition will help implement non-governmental recommendations from the report and work with industry leaders on education, accessibility, and daily UV protection behavior change.

Why does the UK UV safety report project rising melanoma cases, and how is Solésence (SLSN) responding?

The report notes melanoma cases in the UK are projected to rise 9% by 2038. According to Solésence, it supports comprehensive UV protection campaigns, broader education, and improved access to protective products to help reduce UV-related health risks and encourage everyday sun-safe habits.

What are the key recommendations in the UK UV safety strategy backed by Solésence (SLSN)?

The report’s 29 recommendations seek a national UV safety strategy with long-term campaigns, better education, and wider access to protection. According to Solésence, proposals include classifying UV protection as an essential good and promoting year-round skin health awareness beyond seasonal messaging.

How does Solésence’s UV safety initiative align with its business focus for investors in SLSN stock?

Solésence positions itself as a provider of scientifically driven skin health solutions while supporting public UV safety initiatives. According to Solésence, its goal is to create products for diverse skin types and promote daily UV protection, potentially reinforcing its brand within beauty and life science categories.

Keep reading